Peptide and Protein Drug Delivery
Delivery of biomacromolecular therapeutics is a continuous challenge to efficiently treat numerous serious and debilitating diseases. Our group strives to elucidate the interplay between those macromolecular therapeutics and biological barriers.
Our overall aim is to advance therapy with peptide and protein-based drugs via non-injectable routes of delivery to treat serious chronic and acute diseases, like diabetes, hormonal disorders and infections. We are convinced that only through a mechanistic approach to understanding the detailed interplay between the drugs, excipients, drug delivery systems, and biobarriers, the formulation design of future non-injectable macromolecular therapeutics will emerge.
We focus on the design, development and characterization of drug delivery systems using peptide-based carriers and other polymeric and lipidic excipients that are customized to function as efficient and safe carriers for delivery of the drug to the target. Many targets are intracellular, and we explore how translocation through cell membranes may be improved by using membrane-interacting peptides such as cell-penetrating peptides and/or nano-sized drug delivery systems, thus paving the way for intracellular delivery of peptide and protein therapeutics.
Refining the toolbox of models for studying absorption, metabolism and compatibility is of prime interest. We use biophysical techniques for studying membrane interactions, in vitro cell models to elucidate membrane adhesion, mechanisms of uptake, cellular toxicity etc., and in vivo models to evaluate promising findings.
We have expertise on the use of state-of-the-art in vitro cell culture models that combine cells with biosimilar matrices in order to mimic the environments found throughout the various absorption sites in the human body; i.e. mucus in the respiratory airway and the gastro-intestinal tract.